Elegen’s cell-free gene synthesis platform delivers full-length, high-complexity linear DNA with encoded poly(A) tails up to three times faster and free from bioburden, endotoxins and recombination-mediated variation.
Elegen, a global leader in next-generation cell-free DNA manufacturing, today announced the full commercial launch of ENFINIA™ IVT Ready DNA — engineered for immediate use in in vitro transcription (IVT) and saving weeks in the development of mRNA-based therapeutics.
Plasmid-derived templates for IVT are prone to failure or delays, especially when working with complex sequences. Because they are circular and propagated in bacteria, plasmids also need extra processing and quality checks before they can be used in IVT, adding time and complexity to workflows. Elegen’s ENFINIA IVT Ready DNA breaks the plasmid bottleneck and streamlines development by delivering ready-to-use templates in as few as 10 business days — streamlining mRNA therapeutic development while reducing variability and eliminating contamination risks.
“Researchers can now evaluate and develop novel therapeutic modalities faster than ever,” said Matt Hill, founder and CEO of Elegen. “Producing accurate linear DNA with long poly(A) tails without bacteria eliminates the drawbacks of plasmids, bringing greater speed and reliability to mRNA synthesis.”
Plasmids, by nature, also constrain design, require cumbersome workflows and result in inconsistent quality — slowing AI-driven mRNA development, where speed and complexity are critical. Elegen’s cell-free approach removes these barriers, delivering diverse linear, NGS-verified DNA template designs up to 5.5 kb with encoded poly(A) tails (70–130 nt).
Elegen completed early access testing of hundreds of template designs by over 20 biotech, biopharma, and government partners. The company presented its latest data on the quality and performance of ENFINIA IVT Ready DNA templates in a webinar available on demand.
